pharma · Small Cell Lung Cancer · Metastatic castration-resistant prostate cancer (mCRPC)
Amgen
Amgen is a pharma organization headquartered in Thousand Oaks, USA. Primary therapeutic focus areas include Small Cell Lung Cancer, Metastatic castration-resistant prostate cancer (mCRPC), Cardiovascular Disease, Colorec
Company details
- Status
- Public
- HQ
- One Amgen Center Drive, Thousand Oaks, CA 91320, US
- Founded
- 1980
- Employees
- 40,212
- Programs
- 96
- Drugs
- 124
- Patents
- 25
20170104
Phase 2 · other · Ulcerative Colitis (UC)
20170104 for Ulcerative Colitis (UC) is a Phase 2 program (other) at Amgen with 1 ClinicalTrials.gov record(s).
Internal code 20170104
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Amgen
- Phase
- Phase 2
- Modality
- other
- Indication
- Ulcerative Colitis (UC)
- Status
- active
- Trials
- 1